Grant: Collaborative Health Research Projects
Université de Montréal
$143,325.00
Treatment of Preterm Birth with ProstaglandinF2alpha Receptor Modulators
FY 2015-16
Summary
Preterm birth (PTB) is the leading cause of newborn death and the second leading cause of child death. Children born
preterm often have lifelong health issues, including cerebral palsy, cognitive impairement, blindness, deafness, respiratory
illness and gastrointestinal disorders, as well as chronic diseases such as hypertension and dyslipidemia. Hospital costs
associated with PTB are among the most expensive: premature babies remain hospitalized an average of 11 days longer at
a higher cost compared to term births; newborns born prior to 28 weeks gestation incur major costs (~$100,000/infant). In
spite of a better understanding of risk factors and mechanisms related to premature contractions, and the introduction of
public health prevention programs, the rate of PTB has increased. The economic implications of PTB make it the most costly
medical urgency per patient. These statistics demonstrate that significant savings could be obtained by the development of
effective treatments, which can prolong gestation, so called tocolytic agents. Prostaglandin-F2alpha (PGF2alpha) initiates
labour, induces childbirth, and works in compliment with the small peptide hormone oxytocin, which is commonly used to
induce labor in humans. Towards the development of a new tocolytic agent, we targeted the PGF2alpha receptor (FP) for
two specific reasons: 1) FP expression increases during the initial phase of parturition, and 2) FP ''knock-out'' mice do not go
into labour and must be delivered by cesarian. By creating a series of novel modulators, including peptide-based analogs
proving successful in clinical studies, we have validated FP as a viable target. The proposed research is designed to further
develop our prototypes to provide basic knowledge of the role of FP in parturition, to train highly qualified personnel in
interdisciplinary research, and to develop effective therapy to treat preterm labour (PTL) to enhance quality of life from birth
which impacts throughout life.
Program
Collaborative Health Research Projects
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
478447-2015
Name nom
Lubell, William
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
143325
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Treatment of Preterm Birth with ProstaglandinF2alpha Receptor Modulators
Keyword
NSERC
Application summary
Preterm birth (PTB) is the leading cause of newborn death and the second leading cause of child death. Children born
preterm often have lifelong health issues, including cerebral palsy, cognitive impairement, blindness, deafness, respiratory
illness and gastrointestinal disorders, as well as chronic diseases such as hypertension and dyslipidemia. Hospital costs
associated with PTB are among the most expensive: premature babies remain hospitalized an average of 11 days longer at
a higher cost compared to term births; newborns born prior to 28 weeks gestation incur major costs (~$100,000/infant). In
spite of a better understanding of risk factors and mechanisms related to premature contractions, and the introduction of
public health prevention programs, the rate of PTB has increased. The economic implications of PTB make it the most costly
medical urgency per patient. These statistics demonstrate that significant savings could be obtained by the development of
effective treatments, which can prolong gestation, so called tocolytic agents. Prostaglandin-F2alpha (PGF2alpha) initiates
labour, induces childbirth, and works in compliment with the small peptide hormone oxytocin, which is commonly used to
induce labor in humans. Towards the development of a new tocolytic agent, we targeted the PGF2alpha receptor (FP) for
two specific reasons: 1) FP expression increases during the initial phase of parturition, and 2) FP ''knock-out'' mice do not go
into labour and must be delivered by cesarian. By creating a series of novel modulators, including peptide-based analogs
proving successful in clinical studies, we have validated FP as a viable target. The proposed research is designed to further
develop our prototypes to provide basic knowledge of the role of FP in parturition, to train highly qualified personnel in
interdisciplinary research, and to develop effective therapy to treat preterm labour (PTL) to enhance quality of life from birth
which impacts throughout life.